Patriot Scientific der Highflyer 2006
Ich glaube Ptsc hat in Sachen MMP schon verloren als Sie den Deal mit TPL eingegangen sind. Wundert mich das TPL nicht versucht direkt oder über Umwege Patriot zu übernehmen um komplettt in den Genuss des MMP zu kommen. Scheiß Situation und keine besserung in Sicht.
Wieso soll PTSC irgend etwas verloren haben ?
die gleichen textbausteine seit 2005, naja ....
die gleichen textbausteine seit 2005, naja ....
(vielleicht immer noch kein huhn gefunden)
Kann man eigentliuch nachsehen, wer das bekommen hat ?
Conversation today with Kelly Williams of Alliacense
posted on Oct 21, 09 02:46PM
I spoke with Kelly Williams, the contact person at Alliacense and referenced the announcement dated Oct. 5 which said Wave of MMP Portfolio Licensees on the heels of the reexam success.
I asked her what constitutes a wave, because in my opinion, three licensees does not a wave make LOL. She was very nice when she said that she was not at liberty to discuss specifics but that there is definitely a lot of activity going on and perhaps we may see another announcment by the end of this week.
Don't bite my head off if it doesn't happen. Just passing along information.
Laurie
Case: Patriot Scientific v. Deutsche Bank AG Case No: 09cv1500-LAB (POR)
HON. Larry Alan Burns CT. DEPUTY Rptr.
Present
Plaintiff(s): No appearance.
Defendant(s): No appearance.
Currently on calendar for Monday, October 26, 2009 at 11:15 a.m. is a hearing on Defendant's motion to stay proceedings pending arbitration. Pursuant to Civil Local Rule 7.1(d)(1), the Court finds this motion suitable for decision without oral argument. Accordingly, the hearing on this motion is taken off calendar and this matter is taken under submission. No appearances will be required in this matter on Monday, October 26, 2009. Within seven calendar days, the parties shall file a joint notice informing the Court and parties of the current status of the arbitration in question. If the dates set in the scheduling order are different from the dates stated in Defendant's memorandum in support of its motion at 3:16-21, the notice shall provide current dates. If the dates have changed, the Court is inclined to deny the motion, but if they remain the same, the Court is inclined to grant it.
DATED: October 22, 2009
N HONORAB LARR ALA BURNS
United States District Judge
Patriot Scientific Corporation Announces Force10 Networks Purchase of Moore Microprocessor Patent(TM) Portfolio License
CARLSBAD, Calif., Oct 27, 2009 /PRNewswire-FirstCall via COMTEX/ -- Patriot Scientific Corporation /quotes/comstock/11k!ptsc (PTSC 0.29, 0.00, 0.00%) announced today that Force10 Networks, Inc., a leading manufacturer of Networking Equipment, including Switches, Routers and Convergent Access Devices, has purchased a Moore Microprocessor Patent(TM) (MMP) Portfolio license from the TPL Group. Force10 joins a distinguished roster of over 65 global systems manufacturers that have become MMP Licensees.
The MMP Portfolio patents cover techniques that enable higher performance and lower cost designs, and are fundamental to consumer and commercial digital systems ranging from DVD players, cell phones and portable music players to communications infrastructure, medical equipment and automobiles, which today have dozens of microprocessor-based features and benefits.
About the MMP Portfolio
The Moore Microprocessor Patent Portfolio contains intellectual property that is jointly owned by the privately-held TPL Group and publicly-held Patriot Scientific Corporation (OTCBB: PTSC - News). The MMP Portfolio includes seven U.S. patents as well as their European and Japanese counterparts. It is widely recognized that the MMP Portfolio protects fundamental technology used in microprocessors, microcontrollers, digital signal processors (DSPs), embedded processors and system-on-chip (SoC) devices. Manufacturers of microprocessor-based products can learn more about how to participate in the MMP Portfolio Licensing Program by contacting: mmp-licensing@alliacense.com.
About Patriot Scientific
Headquartered in Carlsbad, California, Patriot Scientific Corporation provides data sharing and secure data solutions for a connected world. Patriot Scientific addresses the expanding market opportunities in the healthcare, justice and public safety industries through its wholly owned subsidiary Patriot Data Solutions Group, Inc. These growth activities are funded with revenues generated, in a large part, from the continuing successful Moore Microprocessor Patent(TM) Portfolio licensing partnership with The TPL Group. Patriot Scientific's integrated core intelligence solution addresses the critical data/information sharing needs of the healthcare industry, the Department of Homeland Security, the Department of Justice, and federal, state, and local public safety and law enforcement agencies. For more information on Patriot Scientific Corporation, visit: www.ptsc.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, patent litigation, technical development risks, seasonality and other risk factors detailed in the company's Securities and Exchange Commission filings
Contact:
Angela Hartley
Investor Relations
ir@ptsc.com
760-547-2700 ext. 102
SOURCE Patriot Scientific Corporation
http://www.ptsc.com/
CUPERTINO, Calif. – October 27th, 2009 – Alliacense today announced that Force10 Networks, a leading manufacturer of Networking Equipment, including Switches, Routers, and Converged Access Devices, has purchased a Moore Microprocessor Patent™ (MMP) Portfolio license from The TPL Group. Force10 joins a distinguished roster of over 65 global systems manufacturers that have become MMP Licensees.
"We commend the Force10 Management team for its timely review of the MMP Portfolio and decisive action to assure that the distribution of Force 10 products will continue uninterrupted” said Roy Maharaj, Vice President, Licensing at Alliacense, adding “the recent success of several MMP patents in re-examinations at the USPTO have led a number of companies back to the negotiating table.”
About Alliacense
Alliacense is a TPL Group Enterprise executing best-in-class design and implementation of Intellectual Property (IP) licensing programs. As a cadre of IP licensing strategists, technology experts, and experienced business development/management executives, Alliacense focuses on expanding the awareness and value of TPL’s IP portfolios. Founded in 1988, The TPL Group has emerged as a coalition of high technology enterprises involved in the development, management and commercialization of proprietary product technologies as well as the design, manufacture and sales of proprietary products based on those technologies and corresponding IP assets. For more information, visit www.alliacense.com.
About the MMP Portfolio™
The MMP Portfolio patents, filed by The TPL Group in the 1980s, include seven US patents as well as their European and Japanese counterparts, cover techniques that enable higher performance and lower cost designs essential to consumer and commercial digital systems ranging from PCs, cell phones and portable music players to communications infrastructure, medical equipment and automobiles.
The MMP Portfolio™ is widely recognized as fundamental technology. The sweeping scope of applications using MMP Portfolio design techniques continues to encourage the world’s leading manufacturers of end-user products from around the globe to become MMP Portfolio licensees. Over 65 global companies from the US, Europe, Japan, Korea and Taiwan have licensed the MMP Portfolio technologies. Manufacturers can learn more about how to participate in the MMP Portfolio™ Licensing Program by contacting: mmp-licensing@alliacense.com.
Market Assessment Underway by PTSC to Complement Strong Product Review
* Press Release
* Source: Patriot Scientific Corporation
* On 10:09 pm EDT, Thursday October 29, 2009
o
Buzz up! 0
o Print
*
Companies:
o Patriot Scientific Corp.
CARLSBAD, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Patriot Scientific Corporation (OTC Bulletin Board: PTSC - News) announced that Eclat Consulting, LLC, ("Eclat") will launch a market validation study of the Company's flagship technology, the Crossflo DataExchange® platform ("CDX"). This follows on the heels of a completed independent assessment conducted by a Fortune 1000 technology firm in which CDX scored very high marks in all significant categories including product stability, code quality, and overall design rigor.
Related Quotes
Symbol Price Change §
PTSC.OB 0.2650 +0.0050§
Chart for PATRIOT SCIENTIFIC
{"s" : "ptsc.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}
The Eclat team, lead by CEO Greg Baroni, recently assisted the Company with an assessment of key management, and has also been working with the Company to identify strategic options for the Company's wholly owned subsidiary, Patriot Data Solutions Group ("PDSG"). Patriot's Board engaged Eclat's team of experienced business consultants to help assess the strategic direction of PDSG and to assist in identifying the optimum operational structure and focus of PDSG.
In addition, Eclat is assisting the Company in its search for a Chief Executive Officer with targeted industry experience able to take the company to the next level of growth and revenue. The market validation study will be an essential tool in framing the competencies sought for the CEO candidate.
About Eclat Consulting, LLC ("Eclat")
Eclat - literally, "brilliance of success." And, put simply, our success is defined by the brilliance of our clients' success. We are a different kind of professional services company - problem solvers who deliver tangible performance improvements. Eclat delivers a comprehensive range of services, including strategic, operational support, healthcare, security, and application services. Proven performance and forward thinking - it's Eclat's foundation. For more information on how Eclat is different, visit: www.eclatllc.com.
About Patriot Scientific
Headquartered in Carlsbad, California, Patriot Scientific Corporation provides data sharing and secure data solutions for a connected world. Patriot Scientific addresses the expanding market opportunities in the healthcare, justice and public safety industries through its wholly owned subsidiary Patriot Data Solutions Group, Inc. These growth activities are funded with revenues generated, in a large part, from the continuing successful Moore Microprocessor Patent(TM) Portfolio licensing partnership with The TPL Group. Patriot Scientific's integrated core intelligence solution addresses the critical data/information sharing needs of the healthcare industry, the Department of Homeland Security, the Department of Justice, and federal, state, and local public safety and law enforcement agencies. For more information on Patriot Scientific Corporation, visit: www.ptsc.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, patent litigation, technical development risks, seasonality and other risk factors detailed in the company's Securities and Exchange Commission filings.
HMMMM........
wenn ich mir so die Webseite anschaue...scheint dies ja ne richtige Pommesbude zu sein......
OMG....was holen die sich Mistfirmen ans Land........
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA - SAN JOSE DIVISION
ACER, INC., ACER AMERICA
CORPORATION AND GATEWAY, INC.,
Plaintiffs,
v.
TECHNOLOGY PROPERTIES LIMITED, PATRIOT SCIENTIFIC CORPORATION,
and ALLIACENSE LIMITED,
Defendants.
SECOND SUPPLEMENTAL JOINT CASE MANAGEMENT CONFERENCE STATEMENT
Date: November 13, 2009
Time: 10:30 a.m.
Dept: Courtroom 3, 5th Floor
Before: Honorable Jeremy Fogel
HTC CORP. AND HTC AMERICA, INC.,
Plaintiffs,
v.
TECHNOLOGY PROPERTIES LIMITED, PATRIOT SCIENTIFIC CORPORATION,
and ALLIACENSE LIMITED,
Defendants.
BARCO, N.V.
Plaintiffs,
v.
TECHNOLOGY PROPERTIES LIMITED, PATRIOT SCIENTIFIC CORPORATION,
and ALLIACENSE LIMITED,
Defendants.
Plaintiffs Acer, Inc., Acer America Corporation and Gateway, Inc. (“Acer”), HTC Corp. and HTC America, Inc. (“HTC”) and Barco N.V. (“Barco”) (collectively, the “Plaintiffs”), along
with Defendants Technology Properties Limited (“TPL”), Patriot Scientific Corporation, and Alliacense Limited (collectively, the “Defendants”), hereby submit the following Second Supplemental Joint Case Management Conference Statement (“CMC Statement”) in advance of the Conference scheduled for November 13, 2009. Procedural Background. On May 1, 2009, Plaintiff Acer filed a Motion to Stay All Proceedings Pending Reexamination of the Patents-In-Suit. HTC filed a similar motion in the related action, 5:08-cv-00882 JF. On June 17, the Court granted a ninety-day stay in the Acer and HTC cases, and sua sponte ordered a corresponding stay in the matter of Barco v. TPL et al. (Case No. 5:08-cv-05398 JF) (the “Barco Matter”). On September 18, 2009, the Court held a case management conference (“CMC”) and considered the parties’ request to maintain the stay in this litigation. Ultimately, the Court decided to maintain the stay until a subsequent case management conference set on November 6,
2009, in which the Court will decide whether or not to continue maintaining the stay. The Court subsequently postponed the case management conference by one week and set it on November 13, 2009. Current Status of Patents-In-Suit The five patents-in-suit have collectively been the subject of fifteen (15) separate requests for reexamination since September 2006. The following developments have occurred since the parties last reported to the Court on September 18, 2009 1. U.S. Patent No. 5,809,336 (the “’336 Patent”) As of filing of this CMC Statement, the Reexamination Certificate has not yet been issued by the U.S. Patent and Trademark Office (“PTO”) since a Notice of Intent to Issue Ex Parte Reexamination Certificate (“NIRC”) was issued on September 11, 2009. One reexamination request filed on August 24, 2009 is still pending before the PTO and is not affected by the NIRC. On September 30, the PTO assigned this latest reexamination request to an examiner to determine whether this request for a reexamination will be granted. A decision is expected by November 24 pursuant to 37 CFR §1.515(a). 2. U.S. Patent No. 5,440,749 (the “’749 Patent”) On September 24, 2009, the PTO merged the three (3) pending reexamination proceedings into a single action. On October 9, 2009, the patentee submitted amendments, including its proposed new claims, as part of the merged reexamination proceeding. The amendments reflected changes found in the Certificate of Correction issued on May 26, 2009, in Reexam No. 90/009,034 (for the ’749 Patent). The PTO is currently considering the combined reexamination request and the patentee’s amendments. 3. U.S. Patent No. 6,598,148 (the “’148 Patent”) On October 2, 2009, the PTO merged the two (2) pending reexamination proceedings into a single action. The PTO is currently considering the combined reexamination request. 4. U.S. Patent No. 5,530,890 Patent (the “’890 Patent”) There have been no significant changes since the parties last reported to the Court that a reexamination had been ordered on April 8, 2009. 5. U.S. Patent No. 5,784,584 (the “’584 Patent”) Although a Reexamination Certificate was issued on July 21, 2009, with an amended Claim 29, Defendants have not yet asserted infringement of the ’584 patent in this litigation. A new reexamination request against the ’584 Patent was filed on October 2, 2009 after the July 21, 2009 Reexamination Certificate and is still pending before the PTO. Joint Statement of Plaintiffs Acer and HTC ln light of the recent developments at the PTO, Acer and HTC believe an additional threemonth stay will allow more intrinsic evidence relevant to claim construction to develop. The most significant development since the last CMC held on September 18, 2009 has been the PTO’s consolidation of the reexaminations for the ’749 and ’148 patents. The PTO appears to be moving on those petitions in an expeditious fashion now that a NIRC for the ’336 patent has been issued. The Court originally stayed this action on the grounds that a limited stay would provide additional intrinsic evidence relevant to claim construction. Such a decision has proven astute. During reexamination of the ’336 Patent, for instance, five (5) of six (6) asserted claims against Acer and HTC will issue with significant amendments,1 and the one remaining asserted claim was voluntarily cancelled by Defendants. Now, with the reexaminations for the ’749 and ’148 Patents merged, an additional three-month stay would likewise be beneficial to allow final actions for a 1 TPL originally asserted that Acer and HTC infringed claims 1, 3, 6, 7, 9, 10 of the ’336 patent. TPL voluntarily cancelled claim 3 during reexamination, as well as two claims that have not been asserted. The remaining five (5) claims (1, 6, 7, 9 and 10) have been amended during reexamination. majority of the remaining patents-in-suit.2
Such a stay will not prejudice the Defendants, as demonstrated by the reexamination experience of the ’336 Patent, because none of the claims survived the reexamination in their original form, with all of them either significantly amended or completely cancelled. In particular, the Examiner has added limitations to the now undeniably narrower claims to specifically overcome prior art that was not overcome before. Among the ’336 Patent’s original claims 1 through 10, all independent claims 1, 6, 9 and 10 have been amended (hence so have been their dependent claims 2 and 7), while claims 3, 4, 5 and 8 have been cancelled. Because all the (remaining) asserted claims 1, 6, 7, 9 and 10 of the ’336 Patent have been amended, intervening rights apply and Defendants will not be allowed to accuse Acer, HTC or any other parties or non-parties of infringing the ’336 Patent for any product sold prior to the issuance of the upcoming Reexamination Certificate. 35 U.S.C. 252; Seattle Box Co. v. Industrial Crat. & Pack. Inc., 731 F.2d 818 (Fed. Cir. 1984). Hence, all products identified in Defendants’ Patent Local Rule 3-1 disclosures are free form any claim of infringement of the ’336 Patent. The ’749, ’890 and ’148 reexaminations will likely have a similar result. Additionally, the patentee’s actions to date in the reexaminations have provided further intrinsic evidence that will inform the Court’s claim construction on the amended claims of the ’336 Patent and the other asserted patents should Defendants assert them after the Reexamination Certificate issues. All of the patents share a common specification and recite several identical claim elements that will need to be construed (e.g., the term “ring oscillator” is recited in asserted claims of all four of the patents-in-suit). It is therefore likely that proceedings in the reexaminations will further clarify and inform the Court’s claim construction.
Plaintiff Barco’s Statement Barco is not in favor of a lengthy or indefinite stay in this case, and is prepared to proceed as soon as the Court lifts the stay. In particular, Barco believes the stay should be lifted for at least the ’336 Patent as soon as the pending Reexamination Certificate issues. 2 TPL has made no claim of infringement against Acer or HTC as to the ’584 Patent.Defendants’ Statement Defendants agree that an additional 90-day stay would be beneficial to allow the PTO to finish publishing the Reissue Certificate for the ’336 Patent. Defendants expect that the publication of the Reissue Certificate may facilitate settlement negotiations among the parties. However, if the parties are unable to make substantial progress in settling their disputes in this upcoming 90-day stay, Defendants will request that the stay be lifted at the end of the period without need for agreement from the Plaintiffs. Defendants further disagree with Plaintiffs Acer and HTC’s characterization of the reexaminations. First, the amended ‘336 patent claims are identical in scope. The amendments in the soon-to-be-reissued ’336 Patent are merely clarifying, and indeed, are consistent with Judge Ward’s construction and interpretation of the ’336 Patent claims in the prior Texas action. Thus, there are no intervening rights with respect to the amended claims because the amended claims in the ’336 Patent are identical in scope to the original claims. The Patent Act provides that “the reissued patent, to the extent its claims are substantially identical with the original patent, shall constitute a continuation thereof and have effect continuously from the date of the original patent.” 35 U.S.C. § 252. Second, although Defendants cancelled asserted Claim 3 of the ’336 Patent during the reexamination, that claim was immaterial as Plaintiffs still infringe at least claims of the ’336 Patent. Third, the reexam procedure has resulted in six new claims, all of which will be asserted against the Plaintiffs. With regard to the ’148 and ’749 Patents, the PTO merged the multiple proceedings for
each of those patents into a single proceeding for each patent. In each case, Defendants filed a pro forma amendment that simply sought to place the claims of each of the merged reexamination proceedings in the same condition. Defendants expect that the latest challenge to the ’584 Patent will be summarily denied by the PTO because a Reissue Certificate has already issued on this Patent. Finally, there has been no significant activity on the pending reexamination for the ‘890 Patent.
Dated: November 3, 2009
K&L GATES LLP
By: /s/ Timothy P. Walker
Timothy P. Walker
Harold H. Davis
Attorneys for Plaintiffs
ACER, INC., ACER AMERICA CORPORATION and GATEWAY, IN
They made quick work of that one...32 days - Die PTO hat nur 32 Tage gebraucht bis zur Ablehnung!
The rejected 584 reexam in on IFW. See 90/009591. The examiner included the following statement
The 336 request for reexam 90/009457 also relies on patent holder statements. If you discard anything that requester claims with respect to patent holder assertions, none of the prior art is exactly what the requester claims. I honestly don't see how the examiner is going to use that prior art. IMHO the only way he could use it is to go out of his way to spend time researching it and luckily uncovers something that the requestor overlooked that helps validate the prior art as being what the requester claims. Be interested in what others think.
GLTA, Opty
CARLSBAD, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Patriot Scientific Corporation (PTSC:$0.23,00$0.005,02.22%) announced it has taken measures to reduce expenses at its wholly owned subsidiary Patriot Data Solutions Group, Inc. ("PDSG"), while reaffirming its commitment to provide state of the art data-sharing solutions which include the Company's flagship technology, the Crossflo DataExchange® platform ("CDX").
"We have taken measures to restructure PDSG and to rationalize our level of investment in an aggressive move to better position ourselves to service near term opportunities," said Cliff Flowers, PTSC's Interim CEO. "While we are refocusing our efforts to exploit opportunities for the CDX and Vigilys platforms, we are also undertaking to divest ourselves of the Iameter portfolio of data analysis software and programs. The planned Iameter divestiture, in conjunction with already implemented reductions in staffing, contractor engagements, and other expenditures, will reduce PDSG's cash burn by approximately 40 percent," added Mr. Flowers. PTSC based its decision, in part, on preliminary recommendations from its consulting partner, Eclat, and the need to preserve cash resources. Additional considerations were given to PTSC's expected improved traction in the justice and public safety markets, and the excellent results of the recent CDX technology evaluation which included the reassessment of CDX as a core driver for maximizing shareholder value.
The Company also announced that its next shareholder meeting will be held on January 28, 2010 at 2 p.m. (Central Standard Time) at the InterContinental Chicago, 505 North Michigan Avenue, Chicago, Illinois 60611. The move to the Chicago location was undertaken to better accommodate shareholder access from various locations across the country. Further details pertaining to the shareholder meeting will become available in PTSC's proxy statement expected to be filed with the Securities and Exchange Commission on or about December 7, 2009.
About PDSG
Patriot Data Solutions Group, Inc. ("PDSG") provides products and solutions that enable mission-critical applications to significantly accelerate the time to value and reduce total cost of ownership for their data-sharing initiatives. The company's flagship product, the Crossflo DataExchange® solution, helps link systems together and facilitates secure data sharing for any information exchange initiative in the healthcare, public safety and justice markets. The solution has been designed to work directly with a number of national data sharing standards, including HL7 (Health Level 7), NIEM (National Information Exchange Model), and the Global Justice XML Data Model (GJXDM). PDSG's technological innovation is backed by subject matter expertise and proven methodologies, facilitating the rapid exchange of actionable data in mission-critical applications such as clinical quality improvement and emergency services response management.
PDSG has been working with some of the nation's earliest and most innovative data exchange projects including one of the most advanced statewide data-sharing initiatives to be deployed in the United States. PDSG is the data-sharing group of Patriot Scientific Corporation (PTSC:$0.23,00$0.005,02.22%) , which is headquartered in Carlsbad, California . For more information on Patriot Data Solutions Group, visit www.pdsg.com.
About Patriot Scientific (PTSC:$0.23,00$0.005,02.22%) Headquartered in Carlsbad, California, Patriot Scientific Corporation (PTSC:$0.23,00$0.005,02.22%) provides data sharing and secure data solutions for a connected world. Patriot Scientific (PTSC:$0.23,00$0.005,02.22%) addresses the expanding market opportunities in the healthcare, justice and public safety industries through its wholly owned subsidiary Patriot Data Solutions Group, Inc. These growth activities are funded with revenues generated, in a large part, from the continuing successful Moore Microprocessor Patent(TM) Portfolio licensing partnership with The TPL Group. Patriot Scientific's (PTSC:$0.23,00$0.005,02.22%) integrated core intelligence solution addresses the critical data/information sharing needs of the healthcare industry, the Department of Homeland Security, the Department of Justice, and federal, state, and local public safety and law enforcement agencies. For more information on Patriot Scientific Corporation (PTSC:$0.23,00$0.005,02.22%) ,
visit: www.ptsc.com.
About Eclat Consulting, LLC ("Eclat")
Eclat - literally, "brilliance of success." And, put simply, our success is defined by the brilliance of our clients' success. We are a different kind of professional services company - problem solvers who deliver tangible performance improvements. Eclat delivers a comprehensive range of services, including strategic, operational support, healthcare, security, and application services. Proven performance and forward thinking - it's Eclat's foundation. For more information on how Eclat is different, visit: www.eclatllc.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, patent litigation, technical development risks, seasonality and other risk factors detailed in the company's Securities and Exchange Commission filings.
Contact:
Patriot Investor Relations
ir@ptsc.com
760-547-2700 ext. 102